Codexis (NASDAQ:CDXS – Get Free Report) and Bionano Genomics (NASDAQ:BNGO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.
Profitability
This table compares Codexis and Bionano Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Codexis | -39.55% | -74.36% | -23.58% |
| Bionano Genomics | -106.58% | -78.78% | -48.54% |
Volatility & Risk
Codexis has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, Bionano Genomics has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.
Earnings and Valuation
This table compares Codexis and Bionano Genomics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Codexis | $70.39 million | 1.68 | -$43.97 million | ($0.34) | -3.18 |
| Bionano Genomics | $28.51 million | 0.56 | -$26.40 million | ($3.02) | -0.38 |
Bionano Genomics has lower revenue, but higher earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
78.5% of Codexis shares are held by institutional investors. Comparatively, 11.3% of Bionano Genomics shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 0.7% of Bionano Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Codexis and Bionano Genomics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Codexis | 1 | 1 | 2 | 0 | 2.25 |
| Bionano Genomics | 1 | 0 | 1 | 0 | 2.00 |
Codexis presently has a consensus target price of $6.50, suggesting a potential upside of 501.85%. Bionano Genomics has a consensus target price of $6.00, suggesting a potential upside of 421.74%. Given Codexis’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Codexis is more favorable than Bionano Genomics.
Summary
Codexis beats Bionano Genomics on 12 of the 14 factors compared between the two stocks.
About Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
About Bionano Genomics
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.
